Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study - IHU ICAN – Institut de Cardiométabolisme et Nutrition Accéder directement au contenu
Article Dans Une Revue Annals of Intensive Care Année : 2022

Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study

Thibaut Belmondo
  • Fonction : Auteur
Raphaël Bellaïche
  • Fonction : Auteur
Zakaria Ait-Hamou
  • Fonction : Auteur
Damien Roux
  • Fonction : Auteur
Raphael Clere-Jehl
  • Fonction : Auteur
Elie Azoulay
Stéphane Gaudry
  • Fonction : Auteur
Mélodie Parfait
  • Fonction : Auteur

Résumé

Background: Auto-antibodies (auto-Abs) neutralizing type I interferons (IFN) have been found in about 15% of critical cases COVID-19 pneumonia and less than 1% of mild or asymptomatic cases. Determining whether auto-Abs influence presentation and outcome of critically ill COVID-19 patients could lead to specific therapeutic interventions. Our objectives were to compare the severity at admission and the mortality of patients hospitalized for critical COVID-19 in ICU with versus without auto-Abs. Results: We conducted a prospective multicentre cohort study including patients admitted in 11 intensive care units (ICUs) from Great Paris area hospitals with proven SARS-CoV-2 infection and acute respiratory failure. 925 critically ill COVID-19 patients were included. Auto-Abs neutralizing type I IFN-α2, β and/or ω were found in 96 patients (10.3%). Demographics and comorbidities did not differ between patients with versus without auto-Abs. At ICU admission, Auto-Abs positive patients required a higher FiO2 (100% (70-100) vs. 90% (60-100), p = 0.01), but were not different in other characteristics. Mortality at day 28 was not different between patients with and without auto-Abs (18.7 vs. 23.7%, p = 0.279). In multivariable analysis, 28-day mortality was associated with age (adjusted odds ratio (aOR) = 1.06 [1.04-1.08], p < 0.001), SOFA score (aOR = 1.18 [1.12-1.23], p < 0.001) and immunosuppression (aOR = 1.82 [1.1-3.0], p = 0.02), but not with the presence of auto-Abs (aOR = 0.69 [0.38-1.26], p = 0.23). Conclusions: In ICU patients, auto-Abs against type I IFNs were found in at least 10% of patients with critical COVID-19 pneumonia. They were not associated with day 28 mortality.
Fichier principal
Vignette du fichier
s13613-022-01095-5.pdf (852.14 Ko) Télécharger le fichier
Origine : Publication financée par une institution
licence : CC BY - Paternité

Dates et versions

hal-03983169 , version 1 (15-05-2024)

Identifiants

Citer

Romain Arrestier, Paul Bastard, Thibaut Belmondo, Guillaume Voiriot, Tomas Urbina, et al.. Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study. Annals of Intensive Care, 2022, 12 (1), pp.121. ⟨10.1186/s13613-022-01095-5⟩. ⟨hal-03983169⟩
13 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More